
Acrotech Biopharma, a subsidiary of Aurobindo Pharma, has launched Adquey (difamilast 1%) in the US for mild-to-moderate atopic dermatitis. The non-steroidal topical ointment, licensed from Japan's Otsuka Pharmaceutical, is approved for adults and children aged two and above. It competes with Arcutis Biotherapeutics' Zoryve and Pfizer's Eucrisa in a market estimated at around $1.3 billion for the 12 months ending July 2026, according to IQVIA MAT data cited by multiple outlets.

Acrotech has established a dedicated dermatology business unit to support the launch. CNBC-TV18 reports that Nuvama estimates peak sales of about $300 million with a net present value of Rs 40 per share, and notes the drug has patent protection until 2036. The outlet also says 18 of 28 analysts have a 'buy' rating on Aurobindo. Ashish Anvekar, President of Acrotech Biopharma, called the launch an important milestone. US sales account for about 40% of Aurobindo's revenue.
Update, 3 October 2026: Telangana Today reports the same launch, confirming the product details, the licensed origin and the new dermatology unit. The outlet quotes Ashish Anvekar saying the company is establishing a dedicated dermatology platform. No new financial figures or analyst estimates are added.
All six sources cover the same launch as a straight business story, differing only in the detail each includes. CNBC-TV18 and The Economic Times add Nuvama's peak sales estimate of $300 million, patent protection until 2036 and analyst ratings, giving the coverage a market-news slant. Telangana Today and The Hindu report the launch and the new dermatology unit without financial projections, sticking to the company statement. The uniform core confirms the product details, the licensed origin and the market size, leaving no framing conflict. The next watch item is the product's commercial performance against the $1.3 billion market.
Coverage: 6 sources, 6 neutral
Sources (6): economictimes.indiatimes.com (neutral report), thehindu.com (neutral report), thehindubusinessline.com (neutral report), cnbctv18.com (neutral report), cnbctv18.com (2) (neutral report), telanganatoday.com (neutral report)
This brief was synthesised by AI from the 6 sources linked above, so one read covers every framing they carry. Methodology and corrections.